Cargando…

Identification and characterization of RET fusions in advanced colorectal cancer

There is an unmet clinical need for molecularly directed therapies available for metastatic colorectal cancer. Comprehensive genomic profiling has the potential to identify actionable genomic alterations in colorectal cancer. Through comprehensive genomic profiling we prospectively identified 6 RET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le Rolle, Anne-France, Klempner, Samuel J., Garrett, Christopher R., Seery, Tara, Sanford, Eric M., Balasubramanian, Sohail, Ross, Jeffrey S., Stephens, Philip J., Miller, Vincent A., Ali, Siraj M., Chiu, Vi K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745701/ https://www.ncbi.nlm.nih.gov/pubmed/26078337

Ejemplares similares

RET fusions observed in lung and colorectal cancers are sensitive to ponatinib
por: Gozgit, Joseph M., et al.
Publicado: (2018)

A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions
por: Estrada-Zuniga, Cynthia M., et al.
Publicado: (2022)

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020)

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset
por: Nagasaka, Misako, et al.
Publicado: (2023)

Cancer comes of age embryonically
por: Chiu, Vi K., et al.
Publicado: (2016)

ALK, ROS1, RET and NTRK1–3 Gene Fusions in Colorectal and Non-Colorectal Microsatellite-Unstable Cancers
por: Mulkidjan, Rimma S., et al.
Publicado: (2023)

Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
por: Guo, Robin, et al.
Publicado: (2019)

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes
por: Lu, Chang, et al.
Publicado: (2022)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts
por: le Rolle, Anne-France, et al.
Publicado: (2015)

Cystic brain metastases and RET fusion in lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
por: Santoro, Massimo, et al.
Publicado: (2020)

Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture‐Based Assay of Circulating Tumor DNA
por: Lai, Andrea Z., et al.
Publicado: (2017)

Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors
por: Sigal, Darren S., et al.
Publicado: (2018)

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer
por: Watanabe, Satomi, et al.
Publicado: (2021)

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
por: Hayashi, Takuo, et al.
Publicado: (2021)

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
por: Osta, Badi El, et al.
Publicado: (2020)

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines
por: Kim, Sun Young, et al.
Publicado: (2018)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

RET rearrangements are actionable alterations in breast cancer
por: Paratala, Bhavna S., et al.
Publicado: (2018)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

Genomic landscape of 891 RET fusions detected across diverse solid tumor types
por: Parimi, Vamsi, et al.
Publicado: (2023)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
por: Yokota, Tomoya
Publicado: (2022)

The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
por: Ke, Jun-yi, et al.
Publicado: (2023)

Neuroblastoma in a transgenic mouse carrying a metallothionein/ret fusion gene.
por: Iwamoto, T., et al.
Publicado: (1993)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

RET Protein Expression in Colorectal Cancer; An Immunohistochemical Assessment
por: Ashkboos, Maryam, et al.
Publicado: (2021)

RET is a potential tumor suppressor gene in colorectal cancer
por: Luo, Yanxin, et al.
Publicado: (2012)

Ret-dependent and Ret-independent mechanisms of Gfl-induced sensitization
por: Schmutzler, Brian S, et al.
Publicado: (2011)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

RET Fusion Genes in Korean Non-Small Cell Lung Cancer
por: Yoo, Seung Soo, et al.
Publicado: (2013)

Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review
por: Takeuchi, Kengo
Publicado: (2019)

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
por: Zhao, Lu, et al.
Publicado: (2022)

Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway
por: Lin, Chen, et al.
Publicado: (2016)

The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research
por: Meng, Yan, et al.
Publicado: (2022)

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers
por: Adashek, Jacob J., et al.
Publicado: (2021)

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_05mgl96i1c8v5ic4j5cs9e677o